Using a methicillin-resistant Staphylococcus aureus model, a bacteria responsible for hospital-acquired infections that is resistant to treatment from a class of antibiotics called beta-lactams, which includes penicillin, researchers looked to interrupt the way the bacteria constructs the cell walls that protect it from drugs. After applying a blocker to MRSA cells that interfered with the genes that produce acid to strengthen the bacteria’s cell walls, they identified a chemically altered compound that enabled MRSA to grow normally and made 82 percent of tested strains susceptible to antibiotics.
The researchers are now seeking patents for the two molecules. The synthesis of such chemicals could be an effective strategy to combating antibiotic resistance, in addition to implementing better prescription and stewardship practices and the hundreds of millions of dollars being spent on identifying new classes of antibiotics.
More articles on infection control:
New York health department to offer free Zika testing for pregnant women
Bacterial blood streaminfection linked to 18 deaths in Wisconsin
Cleveland Clinic: First uterus transplant in US is unsuccessful
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
